Get the Stockscreener App
23.75
1.08%
-0.26
After Hours:
23.67
-0.08
-0.34%
Hims Hers Health Inc stock is traded at $23.75, with a volume of 14.48M.
It is down -1.08% in the last 24 hours and down -18.13% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$24.01
Open:
$24.09
24h Volume:
14.48M
Relative Volume:
0.42
Market Cap:
$5.50B
Revenue:
$2.35B
Net Income/Loss:
$128.37M
P/E Ratio:
45.49
EPS:
0.5221
Net Cash Flow:
$57.42M
1W Performance:
-5.19%
1M Performance:
-18.13%
6M Performance:
-31.58%
1Y Performance:
-55.62%
1-Day Range:
$23.30
$24.52
1-Week Range:
$21.53
$24.52
52-Week Range:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
23.75 | 5.56B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | JP Morgan | Overweight |
| Mar-10-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-10-26 | Upgrade | Citigroup | Sell → Neutral |
| Mar-09-26 | Upgrade | Needham | Hold → Buy |
| Feb-24-26 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
HIMS stock extends 3-day rally: Hims & Hers targets GLP-1 gold rush in Canada after Novo Nordisk patent expiry - MSN
Four telehealth platforms now offer generic semaglutide - Benefits and Pensions Monitor
Hims & Hers Health stock price forecast: $22.50 support as HIMS trades down - Traders Union
(HIMS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Hims & Hers Health (HIMS) Stock Forum and Discussion - Moomoo
HIMS stock slips overnight: Hims & Hers bulks up debt raise to $350M for Eucalyptus buyout, AI push - MSN
Hims & Hers Health Inc. Class A (HIMS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Hims & Hers Health Options Spot-On: On May 22nd, 109.56K Contracts Were Traded, With 1.05 Million Open Interest - Moomoo
Hims & Hers (HIMS) CMO-director gets 435 RSUs instead of $10K cash retainer - Stock Titan
Hims & Hers (HIMS) director Christopher Payne awarded 647 RSUs for Q1 2026 fees - Stock Titan
Hims & Hers Health (HIMS) director awarded 957 RSUs for Q1 fees - Stock Titan
Latham Advises on Hims & Hers Health, Inc.’s Upsized US$350 Million Convertible Senior Notes Offering - Latham & Watkins LLP
HIMS Maintained by Truist Securities -- Price Target Raised to $23 - GuruFocus
Hims & Hers Deepens Personalized Care Through Platform Expansion - TradingView
Hims & Hers Has Fallen 66% From Its Peak. Does the $350M Debt Raise Signal a Turning Point or a Red Flag? - TIKR.com
Truist raises Hims and Hers stock price target on GLP-1 insights - Investing.com
Hims & Hers Health, Inc. Announces Issuance of 0.00% Convertible Senior Notes Due 2032 and Indenture with U.S. Bank Trust Company - Minichart
HIMS Stock Price, Quote & Chart | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry - Yahoo Finance
Hims & Hers Health Inc (HIMS) Stock Up 4.2% and Still Undervalued -- GF Score: 77/100 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers H - The National Law Review
Hims & Hers Health issues $402.5 million in convertible senior notes due 2032 - Investing.com
Hims & Hers Health Raises $402.5 Million Via 0% Convertible Notes; Adds Capped Calls at $50.15 Cap - TradingView
Hims & Hers (NYSE: HIMS) issues $402.5M 2032 zero-coupon convertibles - Stock Titan
Hims & Hers stock gains on Canada GLP-1 launch By Investing.com - Investing.com Nigeria
Hims & Hers stock gains on Canada GLP-1 launch - Investing.com
Canadians can now get digital prescriptions for 'generic Ozempic' - Financial Post
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry - Reuters
The Silver Lining of Last Week's Hims & Hers Earnings Miss - MarketBeat
Is Hims and Hers Health Stock a Buy After Its Latest Dip? - AOL.com
HIMS Launches Generic Semaglutide in Canada - GuruFocus
Why Hims & Hers Health Stock Just Crashed - AOL.com
Hims & Hers launches generics for Novo’s semaglutide in Canada - Seeking Alpha
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide - HIMS Investor Relations
Hims & Hers Introduces Access to Generic Semaglutide for Canadian Customers - Hims & Hers Newsroom
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada - Business Wire
HIMS Stock Midweek Analysis | Hims & Hers Health, Inc. (HIMS) Stock Forecast (IK4SVsTRUr) - fathomjournal.org
Hims & Hers Health Q1 2026: Strategic Shift to Branded Medications Weighs on Results - IndexBox
Eucalyptus acquisition prospect lifts Hims & Hers Health stock 2.67% higher - Traders Union
HIMS Becomes a Retail Sentiment Standout as Bullish Mentions Rise to 70% - openPR.com
HIMS Stock Chart | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
HIMS Stock Slips Overnight: Hims & Hers Bulks Up Debt Raise To $350M For Eucalyptus Buyout, AI Push - Stocktwits
Live Longer and Better. Does Medicine’s New Obsession Really Work? - Barron's
Hims & Hers Health, Inc. - dailyvoice.com
Hims & Hers stock slips as dilution fears outweigh new capital - MSN
Hims & Hers Stock Slips As Dilution Fears Outweigh New Capital - Benzinga
Hims & Hers: Wegovy Deal Fuels Growth (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Swings to First-Quarter Loss as Weight-Loss Pivot Drives Up Costs - WSJ
Barclays Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $29 - Moomoo
5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings Call - Yahoo Finance
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):